CTCs
The Indian liquid biopsy company recently launched its Trublood tests for prostate cancer and pan-cancer detection using circulating tumor cells.
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.
TellBio Raises $5M in Series A Round, Inks Deals With Genetron, ARUP for Liquid Biopsy Platform
The startup's strategic agreements with Genetron Holdings and ARUP Laboratories will accelerate global deployment of its TellDx liquid biopsy platform.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept Q4 Revenues Spike as COVID-19 Testing Continues to Soar, Core Cancer Tests Lag
The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.